CEO SUMMARY: Just as Nero is reputed to have fiddled while Rome burned, officials at CMS seem to be doing their own fiddling as their planned deep price cuts to Medicare Part B lab tests could begin driving lab companies out of business. In recent weeks, the owners of two lab companies decided to sell
Tag: national pathology lab
IN THE 2000S, DIGITAL PATHOLOGY WAS THE HOT NEW TECHNOLOGY that held great potential to transform anatomic pathology in myriad ways, not the least of which was an essential tool to streamline pathologist workflow while supporting greater diagnostic precision.
Yet today, approximately 10 years later, those high hopes for the digital pathology market have not come
CEO SUMMARY: There’s a new competitor in the digital pathology marketplace with ambitious plans to deliver a fully-integrated pathologist workflow solution. Inspirata, Inc., of Tampa, Florida, made its debut in March at an international pathology conference. In this exclusive interview, Inspirata Chairman and CEO Satish K. Sanan explains his company’s strategic vision for digital pathology, along with the details of how Inspirata intends to overcome digital pathology’s return-on-investment challenge.
BOTH OF THE NATION’S LARGEST clinical laboratory companies reported increased specimen volume as a result of the Accountable Care Act (ACA), as noted in their respective fourth quarter and full-year earnings reports.
CEO SUMMARY: There’s a day of reckoning on the way for the traditional business model of the private pathology group practice. At most risk are smaller pathology groups that typically have five or fewer pathologists. Blame it on the reduced prices that Medicare and private insurers are paying for pathology services. Another factor is the
CEO SUMMARY: Based on an impressive number of 4,230,129 vials collected from 437,937 biopsies, the new study is expected to add fuel to the fire of the ongoing debate about the appropriate number of prostate biopsies physicians should collect and refer to pathology labs for cancer testing. The researchers compared the number of prostate biopsies
CEO SUMMARY: How will pathology laboratories respond to the publication of revised policies in how laboratories should file Medicare Part B claims for prostate biopsies? Not only will there be a sharp drop in the reimbursement paid for a 12-core prostate biopsy, but labs may be at increased risk of a RAC audit, along with
CEO SUMMARY: It started about eight years ago and shows no signs of slowing down. Specialist physicians, particularly urologists and gastroenterologists, have learned about the benefits of operating their own in-clinic anatomic pathology laboratories. One-by-one, these specialty practices are investing in this ancillary service. As they do, local pathology groups lose access to these tissue
CEO SUMMARY: Events are unfolding rapidly at Bostwick Laboratories, Inc., of Glen Allen, Virginia. In recent months, the company has listed its facilities in Arizona, Tennessee, New York, and Virginia for sale or lease. In July, it agreed to pay a civil fine of $129,000 to settle a consent judgement involving hazardous waste violations at
CEO SUMMARY: In eastern Washington State, InCyte Pathology is developing a strategy that may well be repeated many times over in the coming years. As older pathologists who run smaller groups look to retire, they will consider selling their group practices to larger entities interested in forming regional pathology groups. These larger groups will consolidate